FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365511426> ?p ?o ?g. }

• W4365511426 abstract "Previous clinical randomized controlled trials (RCTs) have demonstrated that immune checkpoint inhibitors (ICIs) cause various toxicities during cancer treatment, but the effects of different inhibitors in combination with chemotherapy for cardiotoxicity remain controversial. The aim of the present study was to assess cardiotoxicity caused by programmed cell death protein 1 (PD-1), programmed cell death-Ligand 1 (PD-L1), and cytotoxic T lymphocyte associate protein-4 (CTLA-4) in combination with chemotherapy to treat lung cancer.The following ICIs were included in the present study: durvalumab, avelumab, ipilimumab, atezolizumab, pembrolizumab, cemiplimab, and nivolumab. The relevant information was extracted using a predefined data extraction table, and the risk of bias was assessed in randomized controlled trials using the Cochrane Bias Risk tool. The main outcomes were hypertension, heart failure, pericardial effusion, and other adverse cardiac events. The random effects model was used to conduct a paired meta-analysis, and a random effects network meta-analysis was then performed within a Bayesian framework.In total, 17 RCTs were included in the present study. There were 11,063 individuals in the experimental and control groups, with an average age greater than 60 years. Based on the evaluation of all drug classes in RCTs, CTLA-4+chemotherapy (RR, -0.69 [95% CI, 2.91-1.52] and PD-L1 (RR, -0.21 [95% CI, -1.03-0.60]) were less cardiotoxic than the control arm, which indicated they were safer options for adverse cardiac events. PD-L1 alone was less cardiotoxic than PD-1 alone (RR, -0.57 [95% CI, -1.96-0.82]). Further, the dual immunotarget inhibitor, PD-1+CTLA-4, had the lowest SUCRA value and had the highest cardiotoxicity (SUCRA=9).When classified according to drug type, CTLA-4+chemotherapy is associated with fewer cardiac adverse events compared to other treatments. Dual immunotarget inhibitors are more likely to have adverse cardiac reactions. Therefore, clinicians should consider this evidence when developing an ICI immunotherapy regimen for lung cancer.https://www.crd.york.ac.uk/prospero, identifier CRD42023360931." @default.
• W4365511426 created "2023-04-15" @default.
• W4365511426 creator A5007829944 @default.
• W4365511426 creator A5040588738 @default.
• W4365511426 creator A5061125325 @default.
• W4365511426 creator A5077985298 @default.
• W4365511426 creator A5082531487 @default.
• W4365511426 date "2023-04-14" @default.
• W4365511426 modified "2023-10-14" @default.
• W4365511426 title "Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials" @default.
• W4365511426 cites W1836157568 @default.
• W4365511426 cites W2066671159 @default.
• W4365511426 cites W2077711565 @default.
• W4365511426 cites W2098853737 @default.
• W4365511426 cites W2098923148 @default.
• W4365511426 cites W2104347254 @default.
• W4365511426 cites W2109391487 @default.
• W4365511426 cites W2121796373 @default.
• W4365511426 cites W2148096101 @default.
• W4365511426 cites W2296878578 @default.
• W4365511426 cites W2322068229 @default.
• W4365511426 cites W2325996754 @default.
• W4365511426 cites W2478478625 @default.
• W4365511426 cites W2547133566 @default.
• W4365511426 cites W2560367415 @default.
• W4365511426 cites W2572174216 @default.
• W4365511426 cites W2588681363 @default.
• W4365511426 cites W2603440970 @default.
• W4365511426 cites W2635951006 @default.
• W4365511426 cites W2769632314 @default.
• W4365511426 cites W2774909809 @default.
• W4365511426 cites W2786816161 @default.
• W4365511426 cites W2790175716 @default.
• W4365511426 cites W2888880602 @default.
• W4365511426 cites W2893602866 @default.
• W4365511426 cites W2908684819 @default.
• W4365511426 cites W2913035631 @default.
• W4365511426 cites W2925446385 @default.
• W4365511426 cites W2946386783 @default.
• W4365511426 cites W2946650292 @default.
• W4365511426 cites W2977648831 @default.
• W4365511426 cites W3002425056 @default.
• W4365511426 cites W3007099934 @default.
• W4365511426 cites W3007540950 @default.
• W4365511426 cites W3012080769 @default.
• W4365511426 cites W3016760590 @default.
• W4365511426 cites W3026324639 @default.
• W4365511426 cites W3032431385 @default.
• W4365511426 cites W3048907462 @default.
• W4365511426 cites W3080330000 @default.
• W4365511426 cites W3091399767 @default.
• W4365511426 cites W3091616850 @default.
• W4365511426 cites W3110002524 @default.
• W4365511426 cites W3110814768 @default.
• W4365511426 cites W3110938402 @default.
• W4365511426 cites W3114444876 @default.
• W4365511426 cites W3118615836 @default.
• W4365511426 cites W3120657480 @default.
• W4365511426 cites W3124587416 @default.
• W4365511426 cites W3129022890 @default.
• W4365511426 cites W3134477587 @default.
• W4365511426 cites W3181034934 @default.
• W4365511426 cites W3199241644 @default.
• W4365511426 cites W3203802554 @default.
• W4365511426 cites W4293827132 @default.
• W4365511426 cites W4296036096 @default.
• W4365511426 cites W4310778429 @default.
• W4365511426 cites W4320517828 @default.
• W4365511426 cites W4323362679 @default.
• W4365511426 doi "https://doi.org/10.3389/fonc.2023.1158690" @default.
• W4365511426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37124488" @default.
• W4365511426 hasPublicationYear "2023" @default.
• W4365511426 type Work @default.
• W4365511426 citedByCount "0" @default.
• W4365511426 crossrefType "journal-article" @default.
• W4365511426 hasAuthorship W4365511426A5007829944 @default.
• W4365511426 hasAuthorship W4365511426A5040588738 @default.
• W4365511426 hasAuthorship W4365511426A5061125325 @default.
• W4365511426 hasAuthorship W4365511426A5077985298 @default.
• W4365511426 hasAuthorship W4365511426A5082531487 @default.
• W4365511426 hasBestOaLocation W43655114261 @default.
• W4365511426 hasConcept C121608353 @default.
• W4365511426 hasConcept C126322002 @default.
• W4365511426 hasConcept C143998085 @default.
• W4365511426 hasConcept C168563851 @default.
• W4365511426 hasConcept C197934379 @default.
• W4365511426 hasConcept C2775949291 @default.
• W4365511426 hasConcept C2776256026 @default.
• W4365511426 hasConcept C2776694085 @default.
• W4365511426 hasConcept C2777701055 @default.
• W4365511426 hasConcept C2777742743 @default.
• W4365511426 hasConcept C2778233292 @default.
• W4365511426 hasConcept C2780030458 @default.
• W4365511426 hasConcept C2781433595 @default.
• W4365511426 hasConcept C71924100 @default.
• W4365511426 hasConceptScore W4365511426C121608353 @default.
• W4365511426 hasConceptScore W4365511426C126322002 @default.
• W4365511426 hasConceptScore W4365511426C143998085 @default.
• W4365511426 hasConceptScore W4365511426C168563851 @default.
• W4365511426 hasConceptScore W4365511426C197934379 @default.

• next